Phase III study of integrin antagonist for treatment of dry eye shows mixed results.
A Phase III clinical study of a novel integrin beta antagonist (“Lifitegrast”), sponsored by Shire plc (LSE: SHP; NASDAQ: SHPG), has shown that twice-daily 5%… Read More »Phase III study of integrin antagonist for treatment of dry eye shows mixed results.